Virax Biolabs Group (VRAX) Competitors $0.61 -0.01 (-1.48%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.60 -0.01 (-0.96%) As of 08/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. MBIO, HOOK, MTNB, PHXM, SNSE, INAB, TRAW, CARM, SNPX, and KPRXShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Mustang Bio (MBIO), HOOKIPA Pharma (HOOK), Matinas Biopharma (MTNB), PHAXIAM Therapeutics (PHXM), Sensei Biotherapeutics (SNSE), IN8bio (INAB), Traws Pharma (TRAW), Carisma Therapeutics (CARM), Synaptogenix (SNPX), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Its Competitors Mustang Bio HOOKIPA Pharma Matinas Biopharma PHAXIAM Therapeutics Sensei Biotherapeutics IN8bio Traws Pharma Carisma Therapeutics Synaptogenix Kiora Pharmaceuticals Virax Biolabs Group (NASDAQ:VRAX) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings. Is VRAX or MBIO more profitable? Company Net Margins Return on Equity Return on Assets Virax Biolabs GroupN/A N/A N/A Mustang Bio N/A N/A -29.49% Do institutionals & insiders have more ownership in VRAX or MBIO? 8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 0.2% of Mustang Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer VRAX or MBIO? Virax Biolabs Group currently has a consensus target price of $3.00, suggesting a potential upside of 395.21%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Virax Biolabs Group is more favorable than Mustang Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to VRAX or MBIO? In the previous week, Virax Biolabs Group had 3 more articles in the media than Mustang Bio. MarketBeat recorded 4 mentions for Virax Biolabs Group and 1 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.88 beat Virax Biolabs Group's score of -0.04 indicating that Mustang Bio is being referred to more favorably in the news media. Company Overall Sentiment Virax Biolabs Group Neutral Mustang Bio Very Positive Which has better valuation and earnings, VRAX or MBIO? Virax Biolabs Group has higher revenue and earnings than Mustang Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirax Biolabs Group$10K262.92-$6.06MN/AN/AMustang BioN/AN/A-$15.75M-$78.00-0.02 Which has more volatility & risk, VRAX or MBIO? Virax Biolabs Group has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. SummaryVirax Biolabs Group beats Mustang Bio on 8 of the 11 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.63M$3.07B$5.75B$9.76BDividend YieldN/A2.29%4.08%4.04%P/E RatioN/A20.7883.2726.60Price / Sales262.92386.53541.17113.73Price / CashN/A44.2237.4459.26Price / Book0.488.0710.556.58Net Income-$6.06M-$53.98M$3.27B$265.95M7 Day Performance-20.81%-0.88%0.40%0.17%1 Month Performance-25.22%7.72%7.31%3.90%1 Year Performance-87.00%7.03%46.58%19.67% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group2.8263 of 5 stars$0.61-1.5%$3.00+395.2%-87.0%$2.63M$10K0.005MBIOMustang Bio1.0014 of 5 stars$1.51-1.9%N/A-89.3%$10.93MN/A-0.02100Positive NewsHOOKHOOKIPA Pharma3.3117 of 5 stars$0.88+0.8%$4.50+411.3%-82.6%$10.73M$9.35M-0.15160News CoverageGap DownMTNBMatinas Biopharma0.5846 of 5 stars$2.10-2.3%N/AN/A$10.68MN/A-0.4330PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049SNSESensei Biotherapeutics4.6263 of 5 stars$8.10-0.1%$55.00+579.0%-33.3%$10.21MN/A-0.3840Positive NewsGap UpINABIN8bio3.8359 of 5 stars$2.23+1.8%$180.00+7,971.7%-86.0%$10.12MN/A-0.2420Positive NewsTRAWTraws Pharma1.736 of 5 stars$1.41flatN/AN/A$9.96M$230K0.0217CARMCarisma Therapeutics3.0681 of 5 stars$0.24+5.4%$1.93+708.8%-79.9%$9.95M$10.77M-0.1520Positive NewsSNPXSynaptogenixN/A$7.01-8.4%N/A+47.0%$9.74MN/A-0.704KPRXKiora Pharmaceuticals3.469 of 5 stars$2.82+6.4%$10.00+254.6%-24.9%$9.67M$16.02M-0.9710 Related Companies and Tools Related Companies Mustang Bio Competitors HOOKIPA Pharma Competitors Matinas Biopharma Competitors PHAXIAM Therapeutics Competitors Sensei Biotherapeutics Competitors IN8bio Competitors Traws Pharma Competitors Carisma Therapeutics Competitors Synaptogenix Competitors Kiora Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
